Objective: Sphingolipid (SPL) are associated with glucose dysregulation. Here, we examined plasma SPL profiles in relation to insulin action and secretion in Black and White adults.

Methods: Baseline plasma levels of 58 SPLs (ceramides {CER}, monohexosyl-ceramides {MHC}, sphingomyelins {SM}, sphingosine {SO} and dihydro-SO-1-phosphate {DHS1P}) were assayed using LC-MS/MS. Insulin sensitivity was assessed by euglycemic clamp (ISI) and HOMA-IR; insulin secretion by IVGTT (AIR), HOMA-B and disposition index (DI, i.e, AIR × ISI).

Results: We enrolled healthy offspring of parents with T2DM (75 Black, 65 White; mean age 47.7 ± 9.01 y, BMI 30.4 ± 6.12 kg/m2, FPG 92.9 ± 6.86 mg/dl and 2-hrPG 130 ± 28.8 mg/dl. Total SPLs showed no association with ISI or HOMA-IR but was significantly associated with insulin secretion (AIR, r=0.19, P=0.031; DI r=0.21, P=0.038). There were differential associations between individual SPLs and insulin secretion/sensitivity, but 5 of 58 SPLs (SM C16:0, SM C28:0, SM C28:1, SM C30:1 and SM C34:0) showed concurrent associations with both measures (r=0.16-0.37, P=0.04-<0.0001). Four SPLs were significantly associated with insulin secretion corrected for insulin sensitivity: MHC C14:0 (r=0.24, P=0.016); MHC C26:0 (r=0.23, P=0.025); SM C22:0 (r=0.26, P=0.009); DHS1P (r=0.27, P=0.006). Very long chain SMs correlated with BMI, waist circumference, body fat and lean mass (r=0.19-0.25, P=0.03-0.0004). Plasma CERs and SMs showed significant associations with 2hrPG (r=0.17-0.25, P=0.04-0.003) but not FPG.

Conclusion: Circulating SPLs associate differentially with indices of insulin sensitivity, secretion, and adiposity. Of the 58 individual SPLs assayed, MHC C14:0 and C26:0, SM C22:0 and DHS1P showed the strongest association with insulin secretion corrected for insulin sensitivity.

Disclosure

P. Asuzu: None. N. Mandal: None. J. Y. Wan: None. F. B. Stentz: None. S. Dagogo-jack: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.